BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Entyvio (vedolizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Entyvio (vedolizumab)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06581328-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Entyvio (vedolizumab): Phase 4 readout est. (NCT06581328)
DESCRIPTION:Entyvio (vedolizumab)\, phase 4\, Ulcerative Colitis.\nStudy: A
  Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Di
 sease (CD) in the Community Setting\nEstimated primary completion: 1 May 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/vedolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06581328
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06227910-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06227910)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Di
 sease\nEstimated primary completion: 8 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06227910
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045754-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:Entyvio (vedolizumab): Phase 4 readout est. (NCT06045754)
DESCRIPTION:Entyvio (vedolizumab)\, phase 4\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Uste
 kinumab in Adults With Crohn's Disease\nEstimated primary completion: 28 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vedolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT060
 45754
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06095128-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Entyvio (vedolizumab): Phase 4 readout est. (NCT06095128)
DESCRIPTION:Entyvio (vedolizumab)\, phase 4\, Ulcerative Colitis.\nStudy: A
  Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (
 UC)\nEstimated primary completion: 9 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06095128
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05928039-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Entyvio (vedolizumab): Phase 4 readout est. (NCT05928039)
DESCRIPTION:Entyvio (vedolizumab)\, phase 4\, Crohn's Disease.\nStudy: PATH
 FINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-
 to-Severely Active Ileal-dominant Crohn's Disease\nEstimated primary compl
 etion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 vedolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05928039
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880744-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06880744)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study to Assess the Change in Disease Activity in Adult Participants With
  Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared 
 to Vedolizumab\nEstimated primary completion: August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06880744
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04779320-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT04779320)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn
 's Disease (CD)\nEstimated primary completion: 13 September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04779320
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03221036-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT03221036)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: E
 fficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerati
 ve Colitis\nEstimated primary completion: 24 September 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03221036
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06180382-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Entyvio (vedolizumab): Phase 4 readout est. (NCT06180382)
DESCRIPTION:Entyvio (vedolizumab)\, phase 4\, Crohn's Disease.\nStudy: Comp
 arison of Vedolizumab Treatment to Adalimumab Dose Intensification in Croh
 n's Disease Patients With Loss of Response or Biomarker Activity to Adalim
 umab on First Line With Therapeutic Drug Concentration.\nEstimated primary
  completion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/vedolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06180382
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788340-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Entyvio (vedolizumab): Phase 4 readout est. (NCT06788340)
DESCRIPTION:Entyvio (vedolizumab)\, phase 4\, Ulcerative Colitis.\nStudy: M
 Odel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammat
 ory Bowel Disease\nEstimated primary completion: 30 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06788340
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04407247-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Entyvio (vedolizumab): Phase 1/2 readout est. (NCT04407247)
DESCRIPTION:Entyvio (vedolizumab)\, phase 1/2.\nStudy: Infliximab or Vedoli
 zumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients 
 With Genitourinary Cancer or Melanoma\nEstimated primary completion: 31 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vedolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04407247
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06609447-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Entyvio (vedolizumab): Phase 4 readout est. (NCT06609447)
DESCRIPTION:Entyvio (vedolizumab)\, phase 4\, Ulcerative Colitis.\nStudy: T
 he Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for t
 he Treatment of Moderate Ulcerative Colitis\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 dolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06609447
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614387-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06614387)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: V
 edolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab\nEs
 timated primary completion: 30 April 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06614387
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06100289-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20280516
DTEND;VALUE=DATE:20280517
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06100289)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or
  Crohn's Disease\nEstimated primary completion: 16 May 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06100289
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031233-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Entyvio (vedolizumab): Phase 4 readout est. (NCT06031233)
DESCRIPTION:Entyvio (vedolizumab)\, phase 4.\nStudy: Evaluating the Safety 
 of Shortened Infusion Times for dIfferent Oncological Immunotherapie\nEsti
 mated primary completion: July 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/vedolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06031233
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03219359-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Entyvio (vedolizumab): Phase 2 readout est. (NCT03219359)
DESCRIPTION:Entyvio (vedolizumab)\, phase 2\, Crohn's Disease.\nStudy: Auto
 logous Stem Cell Transplant for Crohn's Disease\nEstimated primary complet
 ion: October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 dolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03219359
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06815003-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:Entyvio (vedolizumab): Phase 2 readout est. (NCT06815003)
DESCRIPTION:Entyvio (vedolizumab)\, phase 2.\nStudy: Vedolizumab Plus Post-
 transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention
  of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoie
 tic Cell Transplantation After Reduced Intensity Conditioning\nEstimated p
 rimary completion: 15 October 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/vedolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06815003
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06257706-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20290103
DTEND;VALUE=DATE:20290104
SUMMARY:Entyvio (vedolizumab): Phase 4 readout est. (NCT06257706)
DESCRIPTION:Entyvio (vedolizumab)\, phase 4\, Crohn's Disease.\nStudy: VECT
 ORS - A Study to Evaluate Transmural Healing as a Treatment Target in Croh
 n's Disease\nEstimated primary completion: 3 January 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06257706
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06443502-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06443502)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3.\nStudy: A Study to Learn About
  the Safety of Vedolizumab and How Well it Works in Children and Teenagers
  With Active Chronic Pouchitis\nEstimated primary completion: 31 January 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/vedolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06443502
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05837897-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20300308
DTEND;VALUE=DATE:20300309
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT05837897)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab in Adult Participants With Moderate to Severe Crohn's D
 isease\nEstimated primary completion: 8 March 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05837897
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576452-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Entyvio (vedolizumab): Phase 4 readout est. (NCT07576452)
DESCRIPTION:Entyvio (vedolizumab)\, phase 4\, Ulcerative Colitis.\nStudy: F
 irST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised 
 Controlled Trial\nEstimated primary completion: 1 June 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07576452
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06405087-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20300812
DTEND;VALUE=DATE:20300813
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06405087)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Long-Term Extension Study of Vedolizumab in Children and Teenagers With U
 lcerative Colitis (UC) or Crohn's Disease (CD)\nEstimated primary completi
 on: 12 August 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 edolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06405087
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06337695-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Entyvio (vedolizumab): Phase 2/3 readout est. (NCT06337695)
DESCRIPTION:Entyvio (vedolizumab)\, phase 2/3.\nStudy: Vedolizumab for the 
 Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer\nEst
 imated primary completion: 1 December 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06337695
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05442567-7@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20330207
DTEND;VALUE=DATE:20330208
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT05442567)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's 
 Disease (CD)\nEstimated primary completion: 7 February 2033. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05442567
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
